The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma : Episode 3

Opinion

Video

April 23, 2024

Locoregional Therapies for Intermediate-Stage HCC

Author(s):

Richard Finn, MD,David James Pinato, MD, MRCP, PhD

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.

EP: 1.Examining the Role of Liver Function in HCC

EP: 2.HCC Staging: Improving Treatment Strategies

Now Viewing

EP: 3.Locoregional Therapies for Intermediate-Stage HCC

EP: 4.HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

EP: 5.Emerging Therapies in Intermediate-Stage HCC

EP: 6.Updates from IMbrave150, LEAP-002, and HIMALAYA Trials

EP: 7.Comorbidity Considerations for HCC Treatment

EP: 8.The Evolving Landscape of Second-Line Therapies in HCC Management

EP: 9.Additional Second-Line Treatments for HCC

EP: 10.Real-World Evidence on Second-Line Therapy Selection and Outcomes

EP: 11.Pioneering Breakthroughs in HCC Treatment

Related Content

December 13th 2024

Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies After Allo-HCT

Aaron Lisberg, MD, assistant clinical professor, medicine, University of California, Los Angeles School of Medicine

August 1st 2024

Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

November 25th 2024

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

James J. Harding, MD, of Memorial Sloan Kettering Cancer Center

November 21st 2024

Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com

November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors